What is the typical titer range of your standard AAV packaging?

We guarantee standard AAV titers: ≥5 × 10¹² vg/mL for small-scale packages and ≥1 × 10¹³ vg/mL for other package sizes. Custom titers are available upon

Which AAV serotypes do you offer?

We provide AAV1, AAV2, AAV5, AAV6, AAV7, AAV8, AAV9, and more upon request.

How do you ensure quality control for AAV packaging?

By default, we provide a target gene plasmid sequencing report and a viral titer certificate. For projects requiring enhanced characterization, we offer a comprehensive suite of additional Quality Control (QC) assays, including: endotoxin detection (LAL assay), mycoplasma testing (PCR method), sterility testing (direct culture method), capsid protein analysis via SDS-PAGE (Silver/Coomassie Blue staining), TEM analysis (providing an empty capsid ratio report), and viral genomic DNA purity assessment (agarose gel electrophoresis).

Can you produce custom AAV vectors for specific applications?

Yes, we offer AI-enhanced custom AAV variant design and packaging.

How long does it take to receive my AAV vectors?

Standard orders can be delivered within as fast as 2 weeks. Custom projects may require 3–8 weeks.

High-Purity AAV Packaging for Gene Therapy Research

Standard AAV Packaging

Cyagen offers high-purity, high-titer AAV vectors for gene therapy and in vivo research. Our optimized three-plasmid system ensures high infection efficiency, low endotoxin levels, and broad serotype compatibility.

Fast & Reliable Delivery

Standard AAV projects ship in as fast as 2 weeks with rigorous QC testing.

Broad Serotype Selection

Offers multiple serotypes for different tissues and applications.

High Purity & Titer

Achieves robust gene expression in dividing and non-dividing cells.

Overview

Workflow

FAQs

Overview

High-Quality AAV Packaging for Gene Therapy

Adeno-associated virus (AAV) vectors are the most widely used viral vectors for gene therapy due to their low immunogenicity, stable expression, and ability to transduce both dividing and non-dividing cells.

Cyagen offers a reliable AAV packaging service with guaranteed high purity, titer, and quality control. Our production process ensures that researchers can receive ready-to-use viral vectors optimized for in vivo and in vitro applications.

Enhancing AAV Gene Delivery: A Case Study in Optimized Serotype Selection
See how customized AAV serotype selection improved gene delivery in a preclinical study, addressing vector tropism, transduction efficiency, and immune response challenges.

Explore Ready-to-Use Mouse Models

Discover over 18,000 validated mouse strains—including knockout, conditional knockout, and humanized models—covering 20+ research areas such as oncology, neurology, and metabolism. All models are supported by detailed genotype data and guaranteed quality, helping you fast-track discovery with confidence.

You Might Also Be Interested In

AAV Vectors Library

Search and order AAVs by serotype, gene, or function

AI-Powered AAV Discovery

Accelerate gene therapy with AI-optimized AAV capsid engineering and testing

Gene Therapy CRO Platform

AI-guided AAV design and full-spectrum preclinical validation

MouseAtlas Model Library

Search and access curated genetically engineered mouse strains

Ophthalmic CRO Platform

Ocular disease models and IND-ready drug evaluation workflows

Neuroscience CRO Platform

Validated CNS models with behavioral and molecular efficacy data

Workflow

Workflow and Delivery

Cyagen’s AAV packaging service ensures high-purity, high-titer virus production with customizable options tailored for gene therapy and biomedical research. Below is an overview of our streamlined workflow, service specifications, and available serotypes.

AAV Technical Workflow

Service Comparison & Deliverables

We provide multiple grades of AAV packaging services, customized for diverse applications to guarantee optimal performance and strict biosafety compliance.

AAV Type	Production Scale	Virus Amount	Titer	Turnaround	QC & Deliverables
Overexpression	Pilot	≥1×10¹² vg	≥5×10¹² vg/mL	5-8 weeks	- Purified AAV particles (selected serotype) - Complimentary control virus - qPCR-based titer quantification - SDS-PAGE & Western blot validation - Endotoxin testing (<10 EU/mL) - Purity validation (≥95%)
	Medium	≥5×10¹² vg	≥1×10¹³ vg/mL
	Large	≥1×10¹³ vg	≥1×10¹³ vg/mL
RNA Interference	Pilot (3+1)	≥1×10¹² vg	≥5×10¹² vg/mL	3-5 weeks
	Medium (3+1)	≥5×10¹² vg	≥1×10¹³ vg/mL
	Large	≥1×10¹³ vg	≥1×10¹³ vg/mL
Knockout	Pilot	≥1×10¹² vg	≥5×10¹² vg/mL	3-5 weeks
	Medium	≥5×10¹² vg	≥1×10¹³ vg/mL
	Large	≥1×10¹³ vg	≥1×10¹³ vg/mL

FAQs

Citation Database

Molecular Therapy: Methods & Clinical Development, March, 2025

Intracranial AAV administration dose-dependently recruits B cells to inhibit the AAV redosing

【Other】

Gut, February, 2025

E-twenty-six-specific sequence variant 5 (ETV5) facilitates hepatocellular carcinoma progression and metastasis through enhancing polymorphonuclear myeloid-derived suppressor cell (PMN-MDSC)-mediated immunosuppression

【Other】

Cell Death & Disease, February, 2025

Mcm5 mutation leads to silencing of Stat1-bcl2 which accelerating apoptosis of immature T lymphocytes with DNA damage

【Other】

Molecular Therapy, February, 2025

Single-cell data-driven design of armed oncolytic virus to boost cooperative innate-adaptive immunity against cancer

【Other】

Request a Virus Packaging Service Consultation

Get expert guidance for your viral vector production needs. Submit your project details and we'll assist you promptly.

Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:

Yes, I want to receive updates on products, services, and events from Cyagen.

You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.

By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.